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Abstract
Cell lines are key tools in cancer research allowing the generation of neoplasias in animal models resembling the initial
tumours able to mimic the original neoplasias closely in vivo. Canine lymphoma is the major hematopoietic malignancy in
dogs and considered as a valuable spontaneous large animal model for human Non-Hodgkin’s Lymphoma (NHL). Herein we
describe the establishment and characterisation of an in vivo model using the canine B-cell lymphoma cell line CLBL-1
analysing the stability of the induced tumours and the ability to resemble the original material. CLBL-1 was injected into
Rag2
2/2cc
2/2 mice. The generated tumor material was analysed by immunophenotyping and histopathology and used to
establish the cell line CLBL-1M. Both cell lines were karyotyped for detection of chromosomal aberrations. Additionally,
CLBL-1 was stimulated with IL-2 and DSP30 as described for primary canine B-cell lymphomas and NHL to examine the
stimulatory effect on cell proliferation. CLBL-1 in vivo application resulted in lymphoma-like disease and tumor formation.
Immunophenotypic analysis of tumorous material showed expression of CD45
+, MHCII
+, CD11a
+ and CD79acy
+. PARR
analysis showed positivity for IgH indicating a monoclonal character. These cytogenetic, molecular, immunophenotypical
and histological characterisations of the in vivo model reveal that the induced tumours and thereof generated cell line
resemble closely the original material. After DSP30 and IL-2 stimulation, CLBL-1 showed to respond in the same way as
primary material. The herein described CLBL-1 in vivo model provides a highly stable tool for B-cell lymphoma research in
veterinary and human medicine allowing various further in vivo studies.
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Introduction
Development of in vitro and in vivo models able to recapitulate
the natural history of cancers and their clinical response to therapy
is an important prerequisite for rapid bench-to-bedside translation
of anticancer therapies [1]. While early stage evaluations can be
done in vitro using cell lines, the more complex experimental tasks
require the establishment of tumor specific in vivo animal models.
Both systems show specific advantages and disadvantages limiting
the respective experimental possibilities. Cell lines are widely used
to generate animal in vivo tumor models in rodents leading to
significant results.
Despite of all the striking achievements generated in these in vivo
rodent models, some major tumor characteristics of naturally
occurring tumors cannot be provided by experimentally induced
tumors or tumors transplanted into immunocompromised animals.
Thus, spontaneous occurring tumor models have been lately
attracting significant interest in cancer research completing the
well-established conventional in vitro and in vivo models [2].
In this context, canine tumors have been considered as valuable
naturally occurring models helping to reveal mechanisms in cancer
development and behaviour. The neoplasias seen in dogs arise
spontaneously and have been described to mimic human tumors
in many ways as e.g. tumor progression, metastatic pattern, and
histology [3]. These facts suggest that also the mechanisms of
tumor development could be similar in large parts between man
and dog, as for example the development of the canine neoplasias
occurs with the background of an intact immune defence and
tumor evasion. Consequently, the combination of in vitro and in vivo
models with spontaneously occurring primary samples and
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research. However, before engaging veterinary patients, in vitro
and in vivo rodent models able to reproduce the tumors as they
occur in dogs will be needed and thus be of great value. Despite of
these advantages the major critical point in this is the capacity of
the induced tumors to mimic the original neoplasia/cell line as
close as possible in vivo and thus these characteristics have to be
evaluated critically.
Focusing on hematopoietic tumors, canine lymphoma is
considered a useful translational model to study the pathogenesis
and treatment of lymphoma due to the fact that dogs share
extensive genome homology with humans
[4,5,6,7,8,9,10,11,12,13,14,15]. The frequency of canine lympho-
ma cases in hematopoietic malignancies is approximately 83%
representing 7% to 24% of all canine neoplasms [16]. The
response of this malignancy to chemotherapy protocols varies
substantially [17] and in contrast to humans, the remission time in
canine lymphoma is much shorter. This compressed clinical
course of disease reduces the time required to perform longitudinal
studies.
In the present study, we show that Rag2
2/2cc
2/2 mice injected
subcutaneously with the canine lymphoma cell line CLBL-1 [18]
develop multicentric lymphoma as observed in canine patients.
Affected organs of the inoculated mice show stable expression of
intra- and extracellular markers in immunophenotyping, antigen
receptor rearrangement, and histology. We derived the cell line
CLBL-1M from the generated tumor material and comparatively
characterised the karyotype of CLBL-1 and CLBL-1M revealing a
strong chromosomal stability. Further, we could show that CLBL-
1 responds in the same way as primary material to DSP30 and IL-
2 stimulation. This represents a stable model of canine diffuse
large B-cell lymphoma (DLBCL) that closely resembles the disease
as it occurs in dogs and humans giving the opportunity for more
accurate preclinical evaluation of investigational therapies against
lymphoma.
Materials and Methods
Cultivation of the CLBL-1 B-cell Lymphoma Cell Line
The cell culture conditions, as well as the characteristics of the
canine B-cell lymphoma cell line CLBL-1 have been described
previously [18].
Animals and Lymphoma Cell Inoculation
Animals. Immunodeficient Rag2
2/2cc
2/2 mice [19,20]
were maintained under specific pathogen-free conditions in the
animal facility of the Institute of Animal Breeding and Genetics,
Department of Biomedical Sciences, University of Veterinary
Medicine Vienna, Vienna, Austria. All animal experiments were
performed according to the rules of the Austrian Animal Law
1989/2005, licence number 66.009/0065l-il 0b/2009 to Dr.
Veronika Sexl. The mice were kept under sterile conditions in
individually ventilated IVC-cages.
After subcutaneous (s.c.) inoculation of the cell line in the right
and left flank of the animals (n=3), these were observed on a daily
basis and sacrificed by cervical dislocation depending on their
clinical status. Beside the clinical status, the size of the tumor was
an additional criterion for euthanasia by allowing the tumors to
grow up to a size of 0.9 cm.
Inoculation of cells. The CLBL-1 cells were harvested from
the cell culture vessel and after a washing step with RPMI 1640
medium (PAA, Pasching, Austria) supplemented with 10% heat
inactivated fetal calf serum (FCS) (PAA) and penicillin 100 U/ml/
streptomycin 0.1 mg/ml (PAA). After counting in an ADVIA120
haematology Analyser (Siemens, Austria) the cell pellet was
washed twice in PBS without Ca2
+ and Mg2
+ (PAA, Pasching,
Austria). The cells were resuspended in PBS with adjusting the cell
count to 1610
6 a ` 100 ml. Immediately before application the cell
suspension was carefully resuspended and aspirated in 1 ml
syringes (Omnifix-F1ml, B. Braun, Germany) and 1610
6 cells
were inoculated s.c. into the right and left flank of the animals
using a 27G3/499 needle (Sterican, B. Braun, Germany). All mice
were female (4–6 weeks old).
Necropsy, Morphology and Histological Staining
After sacrificing the animals, necropsy was performed immedi-
ately on all individuals. Liver, spleen, bone (hind legs), solid
tumorous material from the flank and macroscopically changed
material of ovaries and uterus of affected animals were removed.
One femur and pieces of liver and spleen, tumour, uterus and
ovaries were fixed in 4% neutral buffered formaldehyde. The
femur was additionally decalcified and all samples were paraffin
embedded, cut into 3 mm sections and stained with haematoxylin
and eosin. Immunohistochemical staining was performed on
paraffin sections with a commercial antibody (Dako, Glostrup,
Denmark) for identification of B cell lineage (mouse anti human
CD79acy, dilution 1:4000).
Generation of CLBL-1 Mouse Tumor Derived Cell Line
CLBL-1M
The tumor tissue sample from the flank was cut into small pieces
using a sterile scalpel. Following, the dissected tissue was
transferred into a sterile 25 cm
2 cell culture flask and treated with
3 ml collagenase (0.26%, Collagenase NB8, Serva GmbH,
Heidelberg, Germany) for 2 hours at 37uC. After incubation, the
dissociated cells were transferred into a sterile 10 ml tube and
centrifuged for 10 min at 1000 rpm. After centrifugation the
supernatant was discarded. The resuspended cell pellet was
transferred into a sterile 25 cm
2 cell culture flask and incubated
in 5 ml RPMI 1640 culture medium (Biochrom, Berlin, Germany)
with 20% FCS (fetal calf serum; PAA, Pasching, Austria) 200 U/
ml penicillin and 200 ng/ml streptomycin (Biochrom, Berlin,
Germany) in 5% CO2 at 37uC.
The cells were controlled in a daily routine. Free floating cell
clusters of well-grown culture flasks were subcultivated in upright
standing 75 cm
2 cell culture flasks with 20 ml RPMI twice a week.
The growth curve and the population doubling time were
evaluated and calculated using the method reported previously
in Ru ¨tgen et al. 2010 [18].
Cell Surface and Intracellular Marker Analysis
For analysis of the cells of the cell line CLBL-1 inoculated in the
animals cells derived from the tumorous material were labelled
with anti-canine or anti-human cross-reactive monoclonal anti-
bodies (mAb) listed in Table 1. Most of these mAb were directly
conjugated with fluorochromes (see Table 1 for details). For each
analysis 1610
6 cells were labelled as described previously [18].
The labelled cells were analysed on a FACSCanto II flow
cytometer (BD Biosciences, San Jose, CA, USA) immediately after
staining. For intracellular staining, the IntraStain-Kit (Dako,
Glostrup, Denmark) was used according to manufacturers’
instructions.
For analysis of the cells, tumor material obtained from the mass
in the flank was tested for cell surface and intracellular markers
expressed by the inoculated cell line by flow cytometry (FCM).
Using a reduced cell number of 5610
5 cells per tube, the staining
protocol was the same like for the cell line mentioned above. One
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antibodies using Chrome pure mouse IgG (Jackson ImmunoR-
esearch Laboratories, West Grove PA, USA) before labelling with
the first antibodies. Erythrocytes were lysed using ADG lyse (An
der Grub, Austria) after incubation with the first mAb.
FCM staining of the tumor was performed using a panel of
antibodies, already used in the antibody panel for the cell line and
verifying the canine origin of the cells as the lymphoma cell line
CLBL-1: mouse anti-human CD3:FITC (Clone: CA17.2A12,
Serotec), rat anti-canine CD5:PE (Clone: YKIX322.3, Serotec),
mouse anti-canine CD11a:APC (Clone: HI111, BD), rat anti-
canine CD45:APC (Clone: YKIX716.13, Serotec), mouse anti-
human CD79acy:PE (Clone: HM57, dako) and rat anti-canine
MHCII:FITC (Clone: YKIX334.2, Serotec), (see Table 1).
The cells of the CLBL-1 and the CLBL-1M cell line were
labelled the same way as described above using the anti-canine or
anti-human cross-reactive mAb (Table 1).
Polymerase Chain Reaction for Antigen Receptor
Rearrangements (PARR)
For the polymerase chain reaction for antigen receptor
rearrangement (PARR) assay, total genomic DNA was extracted
from CLBL-1 cells, cells obtained from the induced tumorous
mass located in the flank of one inoculated Rag2
2/2cc
2/2 mouse
and from the mouse tumor derived cell line CLBL-1M using a
commercial kit following the manufacturer’s instructions (GenE-
luteTM Mammalian Genomic DNA Miniprep Kit, Sigma,
Vienna, Austria) including negative extraction controls. The
DNA was eluted with 200 ml elution buffer supplied with the kit.
A5ml aliquot was analyzed on a 0.7% DNA grade agarose gel
(Fisher Scientific, Schwerte, Germany) and visualised after staining
with GelRedTM (Biotium, Hayward, CA, USA) together with a
High Range DNA Ladder (GeneRulerTM High Range DNA
Ladder, ready-to-use; Fermentas, Burlington, Ontario, Canada).
The DNA samples were assayed by amplifying the Cm DNA
control [21], the immunoglobulin heavy chain (IgH) gene
rearrangements with the primer sets CB1, CB2 and CB3 [21]
and the T-cell receptor gamma (TCRc) gene rearrangements with
the primer sets DPA, DPB and DPC [22]. The PCR mixture was
composed of 16 Type-itH Multiplex PCR Master Mix (Qiagen
GmbH, Hilden, Germany), 16 Q-SolutionH (Qiagen), 16
CoralLoadH (Qiagen), 0.2 mM of each nucleotide (PCR Grade;
Promega, Madison, Wis.), 10 pM of each primer (Eurofins MWG
Operon, Ebersberg, Germany) and 100 ng of eluted genomic
DNA as template brought up to 50 ml with molecular biology
grade water (Sigma). Each PCR reaction was carried out in
duplicate including positive and negative PCR controls in each
PCR run. The PCR reactions were carried out using a T Gradient
thermal cycler (Biometra, Go ¨ttingen, Germany) and the thermal
cycling conditions were 94uC for 3 min, followed by 35 cycles at
94uC for 30 s, 60uC for 20 s and 72uC for 20 s. After PCR, the
amplicons were first analysed on a 4% low melting Phor agarose
gel (Biozym Biotech Trading GmbH, Vienna, Austria) and
visualised after staining with GelRedTM (Biotium) together with
a 100-bp Ladder (O’GeneRulerTM 100 bp DNA Ladder, ready-
to-use, Fermentas). To verify the clonality of IgH gene rearrange-
ments, the obtained PCR products were cloned using the pGEM-
T Easy vector system (Promega) and 16 positive bacterial clones of
each transformation were subjected to automated sequencing with
M13 standard sequencing primer (Eurofins MWG Operon).
Cytogenetic Analysis CLBL-1 and CLBL-1M Cells
For chromosome preparation the CLBL-1 and CLBL-1M cells
were cultured in RPMI 1640 as described above. Half the cell
material of a well-grown 75 cm
2 culture flask was used for one
chromosome preparation. Colcemid was added at a final
concentration of 0.1 mg/ml for 2 h before harvesting. Subse-
quently, the cells were incubated for 20 min in hypotonic medium
(1 : 7; RPMI : H2O) in 15 ml conical bottom centrifugation tubes
(Greiner Bio-One, Frickenhausen, Germany) on a MACSmix
Tube Rotator (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) with 12 rpm rotation and finally fixed with metha-
nol/glacial acetic acid (3:1) following routine methods [23]. The
suspension was dropped on ice-cold slides and dried for 5 days at
37uC followed by GTG-banding which was performed as
previously described by [15]. Results were processed and recorded
with BandView, 6.0, MultiSpecies, Applied Spectral Imaging,
Israel. Karyotype description followed the nomenclature proposed
by Reimann et al. [24].
Quantitative Real-time PCR Analyses for Canine MYC
Expression in CLBL-1 and CLBL-1M
Following samples were used for quantitative real-time PCR
analyses: the herein in detail analysed cell lines CLBL-1 and
CLBL-1M, DT08/40 derived from canine neoplastic tissue
characterised by polysomy of CFA13, and a non-neoplastic FNA
lymph node reference sample. All samples were homogenised with
QIAshredder columns accordingly to the manufacturer’s protocol
(Qiagen, Hilden, Germany).
RNA isolation and cDNA syntheses. RNAs from the lymph
node sample and cultured cell lines were isolated using the RNeasy
Mini Kit according to the manufacturer’s instructions (Qiagen,
Hilden, Germany). To avoid genomic DNA contaminations, on-
column DNase digestion with the RNase-Free DNase set (Qiagen,
Hilden, Germany) was performed. cDNA syntheses were done
using 250 ng RNA and the QuantiTect Reverse Transcription Kit
following the manufacturer’s protocol (Qiagen, Hilden, Germany).
MYC and HPRT real-time PCR. Relative quantification of
the canine MYC and HPRT genes were carried out using the
Table 1. Monoclonal antibodies used for flow cytometry for
CLBL-1 before inoculation of the cells, after sacrificing the
inoculated mice and after cultivating the isolated cells in vitro
(CLBL-1M).
Clone Isotype Fluorescence labelling
CD3 CA17.2A12 mIgG1 FITC
CD5 YKIX322.3 rIgG2a FITC, PE
CD8 YCATE 55.9 rIgG1 PE
CD11a HI111 mIgG1 APC
CD21 B-ly-4 mIgG1 APC
CD21 like (anti B-Cell) CA2.106 mIgG1 anti-mouse IgG1-PE*
CD25 P4A10 mIgG1 PE
CD45 YKIX716.13 rIgG2b APC
CD45RA CA4.1D3 mIgG1 anti-mouse IgG1-PE*
CD56 MOC-1** mIgG1 PE
CD79acy HM57 mIgG1 PE
MHC II YKIX334.2 rIgG2a FITC
*Fluorescence labelling was achieved by use of a secondary antibody.
Abbreviations: m = mouse; r = rat; FITC = Fluorescein isothiocyanate,
APC = Allophycocyanin;
PE = Phycoerythrin.
**cross-reactivity pattern for canine lymphocytes lymphocytes [36].
doi:10.1371/journal.pone.0040078.t001
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(Eppendorf AG, Hamburg, Germany).
For analysis of the human target genes, 2 ml of each cDNA were
amplified in a total volume of 20 ml using universal PCR
Mastermix and TaqMan gene Expression Assays for canine
MYC (Assay ID: cf02628821_m1) and HPRT (Assay ID:
cf02626254_g1) (Applied Biosystems, Darmstadt, Germany).
PCR conditions were as follows: 2 min at 50uC and 10 min at
95uC, followed by 40 cycles with 15 s at 95uC and 1 min at 60uC.
All samples were measured in triplicates further non-template
controls and non-reverse transcriptase control reactions were
included.
A precedent efficiency analysis of all PCR assays used in this
study was performed by applying the same templates and
dilutions. Statistical analysis of relative expression of real-time
PCR results was done by using the software tool REST 2009,
version 2.0.13. A p-value of #0.05 was considered as statistically
significant.
DSP30/IL-2 Stimulation
CLBL-1 and CLBL-1M cells (5610
4 cells/well in 100 ml RPMI
1640) were stimulated in 96-well flat bottom plates with 0.5, 1.0
and 5.0 mmol/l CpG-oligonucleotide DSP30 (TIBMolBiol, Berlin,
Germany) and 50, 100 and 500 U/ml human interleukin-2 (IL-2)
(Peprotech GmbH, Hamburg, Germany) in single applications
and in combination (0.5 mmol/l DSP30 combined with 50 U/ml
IL-2; 1.0 mmol/l DSP30 combined with 100 U/ml IL-2;
5.0 mmol/l DSP30 combined with 500 U/ml IL-2).
The stimulation was performed for 24, 48, 72 and 96 h for each
respective stimulation experiment. Each experiment was per-
formed in eight replicates.
Cell Proliferation Assay
Proliferation of cells in response to DSP30 and IL-2 stimulation
was evaluated using a colorimetric cell proliferation ELISA (Roche
Applied Science, Mannheim, Germany). This assay measures the
incorporation of the thymidine analogue 5-bromo-2-deoxyuridine
(BrdU) into newly synthesised DNA of replicating cells by ELISA
using an anti-BrdU monoclonal antibody.
The proliferation assay was carried out according to the
manufacturer’s protocol for suspension cells (Cell proliferation
ELISA, colorimetric, Roche Applied Science, Mannheim,
Germany). The reaction products were quantified by measuring
the absorbance at 370 nm (reference wavelength 492 nm) with
a maximum of 27 single reads over a time period of 30 min
using a scanning multiwell spectrophotometer equipped with the
analysis software Gen 5 (Synergy HT multi-mode microplate
reader, BioTek Instruments Inc., Bad Friedrichshall Germany).
The absorbance results directly correlate to the amount of DNA
synthesis and hereby to the number of proliferating cells.
Results are stated as mean absorbance values expressed as Max
V [delta 370–492]. The proliferation results of each stimulation
experiment were compared to the corresponding unstimulated
reference cells.
Statistics
Results are presented as mean 6 standard deviation. The
Shapiro-Wilk test was applied to test if the data are normally
distributed using OriginPro 8 software (OriginLab Corporation,
Northampton, USA). Based on the outcome of the Shapiro-Wilk
test, the non-parametric one-tailed Wilcoxon matched pairs
signed rank test for related samples was performed to assess the
significance of differences between stimulated and unstimulated
cells using GraphPad Prism Software (GraphPad Software, La
Jolla, USA). Differences were considered statistically significant
for *p#0.05, **p#0.001 to 0.01 and ***p,0.001.
Results
Application of CLBL-1 Cells, Tumorigenicity and Growth
in Rag2
2/2cc
2/2 Mice
CLBL-1 cells were highly tumorigenic in Rag2
2/2cc
2/2 mice.
In all of the subcutaneously inoculated mice (n=3) the acute
lymphoma-like disease strongly affected liver, spleen, bone
marrow, ovaries and uterus. All mice were sacrificed on day 25
showing tumorous masses at the sites of injection (1/3), abdominal
distention (2/3) and depressed behaviour with reduced level of
activity and tarnished looking fur (3/3).
In a preliminary study 2 mice were used as sham control mice
showing no clinical or pathological signs [25].
Post Mortem Examination of the CLBL-1 Inoculated Mice
Macroscopically, livers were enlarged, but did not show tumor
masses in 3/3 individuals. Spleen was enlarged in 2/3 individuals
(Fig. 1D), and the uterus and ovaries were enlarged in 2/3 affected
mice (Fig 1Ca). Two out of three mice showed abdominal
distension pointing to the enlarged spleen, ovaries and uterus and
one mouse (1/3) showed bilateral distensions on the right and the
left flank indicating solid tumor masses referring to the site of
injection (Fig. 1A, 1Cb). All the other abdominal and thoracic
organs (gastrointestinal tract, kidneys, urinary tract, lung) exam-
ined did not show any evidence of the infiltrating lymphoid
population.
Pathohistological examination revealed disseminated infiltrates
of lymphoid cells in liver (3/3), spleen (2/3), bone marrow (1/3),
uterus and ovaries (2/3) (Fig. 2A, B, C, D) and solid tumours
bilaterally of the s.c. sites of injection (0.9 cm Ø) in one out of
three mice (Fig. 2E). The lymphoid cells had round nuclei with 2–
2.5 red cells in diameter. The chromatin was granular or
branched. The nuclei showed a single central nucleolus or
multiple nucleoli nearby the nuclear membrane. The mitotic rate
was high with 6–9 mitoses/400x field. In the subcutaneous
tumorous mass and in one spleen necrosis of small cell groups was
evident whereas in the other localizations single cell necrosis could
be observed. These pathohistologic characteristics refer to a high
grade lymphoma.
Positive staining for CD79acy in IHC confirmed the phenotype
of the CLBL-1 cell line used for injection in liver (3/3), spleen (2/
3), bone marrow (1/3), uterus and ovaries (2/3) and tumor
material (1/3) (Fig. 3A, B, C, D, E).
Immunophenotyping of Tumorous Tissue of Inoculated
Rag2
2/2cc
2/2 Mice
FCM analysis confirmed the presence of MHCII
+ (98.9%) and
CD11a
+CD79acy
+ (95.7%) cells (Figure 4B) in the tumorous
material of the right flank. All cell populations were negative for
CD5 and CD3 confirming the phenotype of the parental CLBL-
1 cell line initially used for injection (Figure 4B). The CLBL-1
cells analysed on the day of inoculation of the cells showed
expression of MHCII
+ (99.8%) and CD11a
+CD79acy
+ (99.3%)
(Fig. 4A) were additionally positive for CD45, CD45RA and
negative for CD8, CD21, CD21 like and CD56 (data not shown)
confirming their stable phenotype as published in Ru ¨tgen et al.,
2010 [18]. The CLBL-1 cells were additionally negative for
CD25 (Fig. 4A).
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the CLBL-1 Induced Tumor - PARR Analysis
CLBL-1 and two representative cell samples from one solid
tumor of the right flank used for the establishment of the cell line
CLBL-1M were analysed by PCR for TCRc and IgH gene
rearrangements yielding a negative result for the TCRc gene and
a single band for the IgH gene indicating a monoclonal result
(Fig. 5A, B, C). In both samples, Cm with about 130 bp served as
PCR positive control (Burnett et al., 2003). The IgH products
centred around 120 bp (Burnett et al., 2003). As TCRc positive
control (Fig. 5D) we used the OSW T-cell line showing an
oligoclonal band centred on 90 bp (Kisseberth et al., 2007).
Establishment and Morphology of the CLBL-1M Cell Line
Initially, the cells derived from a mouse tumor showed an
adherent appearance according to the initial growth status of the
primary material and with the morphology and growth pattern
resembling the original cell line CLBL-1. The primary prepared
tumor cells were cultivated without the addition of supplementing
growth factors. After 7 days of prolonged cultivation the cells
started to proliferate in non-adherent floating clusters (Fig. 6). Up
to now, the CLBL-1M cell line has been maintained in continuous
culture for more than four months and showed a proliferation
doubling time of 26.4 h during exponential growth under standard
culture conditions (Fig.7).
Immunophenotyping of the CLBL-1M Cell Line
FCM of the CLBL-1M cell line showed expression of
MHCII+ (92.6%), and CD11a, and +CD79acy+ (98.6%)
(Fig. 4C). In addition cells were positive for CD45, CD45RA
and negative for CD8, CD21, CD21-like antigen and CD56
(data not shown) Therefore they showed the same expression
pattern as their mother cell line CLBL-1 published in Ru ¨tgen et
al., 2010 [18]. The CLBL-1M cells were additionally negative
for CD25 (Fig. 4C).
Clonal IgH Gene Rearrangement of the CLBL-1M Cells
CLBL-1M were analysed by PCR for TCRc and IgH gene
rearrangements yielding a negative result for the TCRc gene
and a single band for the IgH gene indicating a monoclonal
result (Fig. 5D). Cm with about 130 bp served as PCR positive
control (Burnett et al., 2003). The IgH products centred around
120 bp (Burnett et al., 2003). As TCRc positive control (Fig. 5E)
we used the OSW T-cell line showing an oligoclonal band
centred on 90 bp (Kisseberth et al., 2007). These data confirm
the stable IgH gene rearrangement shown in the initiating cell
line CLBL-1.
Cytogenetic Analyses of the Cell Line CLBL-1 and CLBL-
1M
Cytogenetic investigation of CLBL-1. Chromosome anal-
yses of 21 metaphases revealed a canine hypodiploid karyotype
with several chromosomal changes, including monosomies (e.g.
monosomy 23, monosomy 30), derivative chromosomes (e.g.
der(X)), and centric fusions (Fig. 8A+B). The chromosome number
ranged between 69 and 73 (69 [1], 70 [8], 71 [9], 72 [2], 73 [1]),
with 70 and 71 chromosomes being the predominant number. In
18 metaphases (85.7%) a bi-armed derivative chromosome
(der(13;13)), consisting of two chromosomes 13 and unidentified
Figure 1. Images of immunodeficient Rag2
2/2cc
2/2 mice after s.c. inoculation of the cell line CLBL-1: (A) image of on representative
mouse with solid tumours located at the site of injection (see two arrows black and white) (picture taken from inoculated mouse CLBL1-I), (B) situs of
on representative mouse with solid tumours located at the site of injection (see solid lined arrow) and enlarged ovary and uterus (dotted lined arrow)
(picture taken from inoculated mouse CLBL-1 I), (Ca) ovary (picture taken from inoculated mouse CLBL-1 I) (Cb) tumour mass from injection site
(picture taken from inoculated mouse CLBL-1 I) (D) spleen of two inoculated mice with different extent of infiltration (picture taken from inoculated
mouse CLBL-1 II (Da) + CLBL-1 III (Db).
doi:10.1371/journal.pone.0040078.g001
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Figure 8C four derivative chromosomes (der(13;13)) extracted
from four different metaphases are shown.
Cytogenetic Investigation of CLBL-1M
Cells for the cytogenetic investigation of CLBL-1M were
derived from the injection-site located tumor tissue of a Rag2
2/
2cc
2/2 mouse. Chromosome analyses of 20 metaphases revealed
a karyotype comparable to the CLBL-1 karyotype (Fig. 8D+E).
For CLBL-1M, the chromosome number ranged between 70 and
73 (70 [1], 71 [17], 72 [1], 73 [1]), with clearly 71 chromosomes
being the predominant number. The analyses revealed the same
derivative chromosome (der(13;13)) as described for CLBL-1 in 19
metaphases (95%) (Fig. 8F).
Quantitative Real-time PCR Analyses for MYC Expression
in CLBL-1, CLBL-1M and DT08/40 Cells
The non neoplastic lymph node sample was set as calibrator.
MYC/HPRT expression levels for CLBL-1 and CLBL-1M varied
from 0.621 (CLBL-1) to 0.662 (CLBL-1M) while the expression in
DT08/40 showed 4.61 when compared to the calibrator
(calibrator value was set as 1) (Fig. 9).
Statistics of Relative Real-time PCR
MYC expression is down regulated using HPRT as endogenous
control (housekeeping gene) in CLBL-1 (p=0.000) and CLBL-1M
(p=0.000) when compared to the non neoplastic control sample.
Relative MYC expression of DT08/40 in comparison to control
sample is up regulated (p=0.030).
Proliferation Assay
Primary B-cells, B-cell lymphoid neoplasms and human chronic
lymphatic leukemia (CLL) are reported to have a low in vitro
mitotic activity, but the proliferation can be stimulated by
incubation with the DSP30 CpG-oligonucleotide and IL-2 (Decker
et al., 2000; Haferlach et al., 2007; Struski et al., 2009; Reimann-
Berg et al., 2011). To examine if the initial canine B-cell line
CLBL-1 as well as the Rag2
2/2cc
2/2 mouse tumor-derived
canine CLBL-1M cell line show as well a higher proliferation rate
in response to DSP30 and/or IL-2 stimulation in different
concentrations in comparison to the corresponding unstimulated
cells the cell proliferative activity of the two cell lines was measured
post stimulation with a standard BrdU proliferation test (Cell
Proliferation ELISA BrdU (colorimetric), Roche). The incorpora-
tion of BrdU was assessed over a stimulation period of 24, 48, 72
and 96 h.
Figure 2. Morphologic characteristics of the CLBL-1 cell line as a xenograft tumour in Rag2
2/2cc
2/2 mice. Neoplastic infiltrative cells in
the liver (A), spleen (B), bone marrow (C), ovary (D) and solid tumour mass at injection site (E); (H&E, magnification6400, pictures taken from
inoculated mouse CLBL-1 I).
doi:10.1371/journal.pone.0040078.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40078Figure 3. CD79acy expression of the CLBL-1 cell line as a xenograft tumour in Rag2
2/2cc
2/2 mice. Neoplastic B cells referring to the
characteristics of the inoculated cell line infiltrating the liver (A), spleen (B), bone marrow (C), ovary (D) and solid tumour mass at injection site (E);
(H&E, magnification6200, pictures A, D, E taken from inoculated mouse CLBL-1 I; pictures B,C taken from inoculated mouse CLBL-1 II), bar = 80 mm.
doi:10.1371/journal.pone.0040078.g003
Figure 4. FCM analyses of the CLBL-1 cell line (A) and tumorous material derived from the site of inoculation of CLBL-1 cells (B). In
the left row dot-plots depicting forward/side scatter (SSC/FSC) signals are shown to illustrate gating of the respective lymphocyte populations. Dot-
plots in the three right rows show expression of various antigens of the gated lymphocyte population. Vertical and horizontal lines in the dot plots
mark the boundaries between positive and negative cells for the respective markers as established by corresponding isotype control samples. Per
sample at least 1610
4 of gated cells were analysed.
doi:10.1371/journal.pone.0040078.g004
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could be obtained in all different approaches stimulating CLBL-1
and CLBL-1M cells (data not shown). The BrdU incorporation
assayed 48 h after stimulation of both cell lines was significantly
increased in all samples stimulated with DSP30 and IL-2 in
combination (Fig. 10A and 10D). The 48 h stimulation with
DSP30 alone at all three concentrations (0.5, 1.0 and 5.0 mmol/l)
led to a significant increase of CLBL-1 proliferation with highest
effect at 5.0 mM (Fig. 10A) and for CLBL-1M cells at a
concentration 0.5 mM DSP30 (Fig. 10D) while single IL-2
incubation for 48 hours only increased the proliferation signifi-
cantly at a concentration of 50 U/ml in case of CLBL-1. After
72 h of stimulation with DSP30 and/or IL-2, a similar trend could
be observed for the CLBL-1 as well as the CLBL-1M cell line
(Fig. 10B and 10E). Merely the response of CLBL-1 cells to
stimulation with 50 U/ml IL-2 is not significant anymore whereas
a concentration of 100 U/ml IL-2 showed a significant effect after
72 h stimulation (Fig. 10B). Concerning CLBL-1M cells, the
stimulation with 5.0 mM DSP30 has no longer a significant effect
(Fig. 10E).
The measured proliferation of CLBL-1 cells after 96 h of
stimulation revealed a decreased significance in all single
experiments besides stimulation with 1.0 mM DSP30 and
100 U/ml IL-2 in combination, where a p,0.01 (**) is still given
(Fig. 10C). Concerning CLBL-1M, the 96 h stimulation with
combined DSP30+ IL-2 and with single applied DSP30 in all three
concentrations resulted in significantly increased proliferative
effects. In contrast, sole stimulation with IL-2 showed no
significant effect on the cell proliferation.
Discussion
The establishment of in vivo animal models and cell lines
resembling human tumor diseases is a major tool in translational
cancer research. Many cancers show strong similarities between
the human and canine neoplastic disease including their histolog-
ical appearance, tumour genetics, biologic behaviour and response
to conventional therapies [26].
Lymphoma is one of these cancer types commonly affecting
middle-aged individuals of both species, spontaneously. Due to the
similarities in tumor behaviour and presentation the canine
neoplasia is widely accepted to be a valuable model for human
non-Hodgkin’s lymphoma [4,26,27].
In the present study, we describe the establishment and
characterization of an in vivo lymphoma xenograft mouse model
using a canine B-cell lymphoma cell line to analyse the
tumorigenicity, genomic stability and histological and morpholog-
ical similarity in comparison to the original material.
The used lymphoma cell line CLBL-1 [18] was derived from a
canine diffuse large B-cell lymphoma (DLBCL) representing one
of the most common lymphoma forms occurring in dogs and
humans. The cells were inoculated subcutaneously to generate
solid tumorous material at the injection site and for studying the
homing of lymphoid-derived cells to the organs in the recipient
mice. CLBL-1 in vivo application resulted in lymphoma-like disease
and tumor formation.
All inoculated animals showed a diffuse foreign invasive
population in solid tumor tissue, bone marrow, spleen, liver and
uterus and ovaries detected by pathology, histopathology and
immunohistochemical staining (IHC). Due to the fact that Rag2
2/
2cc
2/2 mice are alymphoid, we were not able to show neoplastic
cells in lymph nodes or mediastinal mass. Rag2
2/2cc
2/2 mice
Figure 5. PCR for antigen receptor rearrangement. PARR of CLBL-1 cells (A), Xenograft-1 (tumor of right flank,B), Xenograft-2
(tumor of right flank,C), CLBL-1M cells (D) and the OSW cell line (E). Lane 1 shows Cm serving as positive control for DNA. Lanes 2 and 3 show
bands of IgH and TCRc PCR products, respectively.
doi:10.1371/journal.pone.0040078.g005
Figure 6. Morphologic appearance of non-adherent CLBL-1M cells. CLBL-1M cells form free floating clumps in the cell culture medium.
Transmitted light images of 100x (A) and 400x (B) magnification.
doi:10.1371/journal.pone.0040078.g006
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mature lymphocytes allowing the investigator to solely detect
inoculated lymphocytes derived from the donor cell line.
Concerning immunohistochemical staining, CD79acy was
chosen as a responsible marker for B-lymphocytes focusing on
the detection of the cells in liver, spleen, bone marrow, ovary and
solid tumour tissue and since the chosen anti-human antibody
crossreacts with canine cells [28]. In a former study characterising
a canine lymphoma T-cell line (Kisseberth et al. 2007), i.v.
injection of canine lymphoma cells in immunodeficient mice
showed growth in the mesentery, pancreas, liver, spleen, lungs,
peri-renal fat and small intestine. Our results using the herein
described B-cell line parallel those findings. The infiltration and
almost complete replacement of the normal cells with the
malignant lymphocytic population in the reproductive organs
was unexpected. To the best of our knowledge, this finding has not
been previously reported in canine lymphoma. In human
medicine, a quarter of the lymphomas arise in extranodal organs
and about 1.5% of extranodal lymphomas primarily originate in
the female genital tract [29], but also secondary involvement in
case of high-stage lymphomas is possible and mostly affects the
corpus besides cervix and ovaries [30]. The most commonly
histological diagnosed type is the DLBCL [30]. These facts known
in human medicine could probably explain the presence of the
inoculated cells in the reproductive tract of the inoculated mice
being characterized as a DLBCL and underline the aggressive
infiltrating character of the established CLBL-1 cell line. Estrogene
and progesterone receptors in lymphomas are known in humans
and horses. In horses the presence of monoclonal antibodies to
nuclear progesterone has been confirmed immunohistochemically
(Henson et al. 2000). In canine lymphoma, these facts are
discussed controversially (Teske et al. 1987; Vicini et al. 1991), but
could be a reason for the presence of infiltration in the organs of
the reproductive tract in the inoculated mice.
Flow cytometric cell surface and intracellular marker analyses of
cells isolated from the tumor mass and the mouse tumor derived
cell line CLBL-1M revealed the same immunophenotypical
characteristics represented by the same antigen expression in
comparison to the original CLBL-1 cell line. The cell surface and
intracellular markers have been chosen according to the original
marker panel used to characterise the parental CLBL-1 cell line.
The cells derived from the tumor mass and the CLBL-1M cell line
stained positive for CD11a, CD79acy, MHCII and negative for
CD3 and CD5. The CLBL-1 and the CLBL-1M cell line show
nearly identical in vitro growth characteristics including prolifera-
tion doubling times represented by 26.4 h in the CLBL-1M cells.
This result is comparable to the published doubling time of the
CLBL-1 cells showing 31 h [18]. These gained results confirm the
Figure 7. Proliferation doubling time of CLBL-1 and CLBL-1M on five consecutive days.
doi:10.1371/journal.pone.0040078.g007
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conclusion that the growth status and the antigen expression
remained stable during tumor formation in the xenograft model.
On the genomic level, the polymerase chain reaction for B- and
T-cell antigen receptor rearrangement (PARR) analysis of the
xenograft material revealed a clonal band for the IgH gene
rearrangement in all samples thus confirming the primordial
origin of the tumorous material and further providing evidence for
its stable phenotype.
The importance of non-random cytogenetic abnormalities in
human leukaemia and lymphoma has been recognised since the
early eighties [31]. Several reports about cytogenetic analyses of
canine lymphoid neoplasms showed that lymphomas in dogs are
characterised by non-random cytogenetic abnormalities as well
[8,12,16,32].
To examine potential cytogenetic changes during tumor
induction in Rag2
2/2cc
2/2 mice, the initial CLBL-1 B-cell
lymphoma cell line as well as the CLBL-1M cell line established
from a tumor located at the injection site of a Rag2
2/2cc
2/2
mouse were cytogenetically analysed and compared. We observed
relatively stable modal chromosome copy numbers in CLBL-1M
compared to CLBL-1. Both expressed the same prominent
derivative chromosome (der(13;13)) and CLBL-1M did not
acquire further chromosomal alterations. Thus we conclude that
chromosomal stability was maintained. A polysomy of CFA 13
could not be detected but aberrations of CFA 13 were described to
be involved in several canine neoplasias including lymphomas
[9,12,16]. Interestingly, the canine orthologue to c-MYC gene is
coded on CFA13 and thus aberrations affecting this chromosome
could be affecting the expression of the gene. Comparative real-
time PCR analyses of MYC expression in CLBL-1, CLBL-1M, a
non neoplastic lymph node sample, and DT08/40 (a canine
prostate cancer cell line showing polysomy of CFA13) showed that
-in contrast to DT08/40- both cell lines do not over-express MYC.
CLBL-1 and CLBL-1M showed a statistical relevant down-
regulation of MYC expression. However, this difference in
expression is in a minor range, probably explainable by regular
biologic variance. In contrast to this, the clear over-expression of
MYC in DT08/40 indicates that the several copies of CFA13 in
this cell line correlate with MYC over-expression. As we were not
able to identify polysomies of CFA13 in CLBL-1 and CLBL-1M
the obtained qPCR data matches the karyotype analysis.
In general, conventional cytogenetic analyses of B-cell lymphoid
proliferations are difficult to perform due to a low mitotic activity
Figure 8. Metaphase spreads after GTG-banding from cells derived from CLBL-1 (A) and from CLBL-1M (D). Corresponding karyotypes
of CLBL-1 (B) and CLBL-1M (E). The arrows indicate the derivative chromosomes der(13;13), comprising of two chromosomes 13 plus unidentified
chromosomal material in the centromeric region. In the boxes four derivative chromosomes (der(13;13)) of CLBL-1 (C) and CLBL-1M (F) extracted from
four different metaphases are shown.
doi:10.1371/journal.pone.0040078.g008
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to gain a sufficient number of metaphases for analyses. For human
chronic lymphatic leukemia (CLL) and B-cell lymphoid neo-
plasms, the immunostimulatory CpG-oligonucleotide DSP30 in
combination with interleukin-2 (IL-2) has been reported to be an
easy and efficient stimulus for metaphase generation [33,34,35].
Figure 9. Relative MYC/HPRT expression in canine CLBL-1, CLBL-1M and DT08/40 cell lines and in a canine lymph node aspirate. Error
bars are standard deviations. * indicates a statistical significant expression deregulation of the MYC gene when compared to non neoplastic control
sample.
doi:10.1371/journal.pone.0040078.g009
Figure 10. BrdU cell proliferation assay. Measured proliferation of CLBL-1 (A, B, C) and CLBL-1M (D, E, F) after stimulation with
DSP30 and/or IL-2 at different time points (48 h, 72 h, 96 h) in comparison to untreated cells. Each bar represents a mean ± SD,
*p#0.05, **p#0.001 to 0.01.
doi:10.1371/journal.pone.0040078.g010
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could successfully be stimulated with concentrations of 1.0 mM
DSP30 and 100 U/ml IL-2 for 72 h resulting in an adequate
number of metaphases [15].
To examine if the initial B-cell line CLBL-1 as well as the
CLBL-1M cell line derived from a Rag2
2/2cc
2/2 mouse tumor
respond in the same dose-dependency as primary B-cells to DSP30
and IL-2 stimulation with a higher mitotic rate, the two cell lines
were incubated with DSP30 and IL-2 to measure the proliferation
subsequently by BrdU incorporation. The highest significant
stimulatory effect on CLBL-1 cells was reached with the combined
application of DSP30 and IL-2 after 72 h stimulation. Concerning
CLBL-1M stimulation, the highest effects were also measured with
DSP30 and IL-2 in combination, but at a stimulation time of 48 h.
After 72 h of stimulation, CLBL-1M showed similar proliferative
responses as CLBL-1 to DSP 30 and/or IL-2 stimulation. Merely
the combination of 5.0 mM DSP30+500 U/ml IL-2 and the single
stimulation with 5.0 mM DSP30 seems less effective on CLBL-1M
cells. Considered in total, the five-fold higher combination of the
stimulating agents (5.0 mM DSP30+500 U/ml IL-2) showed
partially a slightly higher effect, but the difference to the
stimulation with 1.0 mM DSP30+100 U/ml IL-2 is marginal and
the cost-benefit ratio needs to be evaluated case-dependently.
Differences in cell response to the stimulating agents could be
explained by a differential expression of the relevant receptors as
e.g. CD25. FCM analyses for CD25 expression in the analysed cell
lines revealed negative results indicating that the observed different
stimulation response at 48 h is probably mediated by an
alternative way. However, in conclusion we could demonstrate
that the immunostimulatory CpG-oligonucleotide DSP30 in
combination with IL-2 results in higher proliferation rates of
CLBL-1 and CLBL-1M cells and confirm the findings of
Reimann-Berg et al. in primary material [15] with respect to the
applied concentrations of 1.0 mM DSP30 and 100 U/ml IL-2 in
combination.
The results show that during the tumor formation in the
Rag2
2/2cc
2/2 mouse model and subsequent in vitro cell culture,
the CLBL-1 cell line did not lose the capability to respond in the
same way as freshly taken, short term cultured B-cell lymphoma
cells.
In the present study we could show that the canine cell line
CLBL-1 is capable of inducing tumor (lymphoma) formation in
mice. These tumors are morphologically and phenotypically
similar to the canine end-stage disease. This fact makes the model
an interesting candidate for further investigations into the
diagnosis and therapy of canine lymphoma and has the potential
to promote the translational and comparative lymphoma research
in humans and dogs.
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